Cancers, Vol. 11, Pages 517: Cancer Vaccines Co-Targeting HER2/Neu and IGF1R

Conclusions: Multi-engineered adjuvanted cancer cell vaccines can break the tolerance towards a highly tolerized RTK, such as IGF1R. Cell vaccines co-targeting HER2/neu and IGF1R elicited low levels of specific antibodies that slightly delayed onset of HER2/neu-driven, IGF1R-dependent tumors.

Source: Cancers - April 10, 2019 Category: Cancer & Oncology Authors: Carla De Giovanni Lorena Landuzzi Arianna Palladini Marianna Lucia Ianzano Giordano Nicoletti Francesca Ruzzi Augusto Amici Stefania Croci Patrizia Nanni Pier-Luigi Lollini Tags: Article Source Type: research